RxDoctor Payments Data

Maria Pavez, MD

Neurology · Somerset, KYNPI 1114967239

Payments from drug & device makers

$9,361in general payments, 2019–2025

Across 466 payments — averaging $20.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$2K
  • AbbVie$2K
  • UCB, Inc.$908
  • Teva Pharmaceuticals USA, Inc.$540
  • Lilly USA, LLC$418
  • Jazz Pharmaceuticals Inc.$386
  • plus $4K from 38 others

What the payments were for

  • Speaking & faculty fees$260%
  • Travel & lodging$1,01411%
  • Food & beverage$8,27988%
  • Education$410%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,361 in reported general payments places this provider in the 65th percentile of 210 neurology providers in Kentucky.

See all neurology providers in Kentucky

Medicare billing

Part B allowed, 2024
$48,476
Medicare patients
243
Services billed
491

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine11$151,407
NuplazidPimavanserin Tartrate14$57,446
Emgality PenGalcanezumab-Gnlm40$32,176
RytaryCarbidopa/Levodopa27$20,174
UbrelvyUbrogepant12$18,509
Nurtec OdtRimegepant Sulfate12$17,453
HorizantGabapentin Enacarbil27$14,270
QuliptaAtogepant12$12,863
Entacapone47$3,227
Pregabalin84$1,860
Pyridostigmine Bromide11$1,719
Carbidopa-Levodopa ErCarbidopa/Levodopa45$1,634
Carbidopa-LevodopaCarbidopa/Levodopa61$1,488
Memantine Hcl88$1,428
Lacosamide13$1,233

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$540$151,40711 claims
Acadia Pharmaceuticals IncNuplazid$178$57,44614 claims
AbbVieUbrelvy, Qulipta$1,517$31,37224 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$81$21,89338 claims
PfizerNurtec Odt$193$17,45312 claims
Arbor Pharmaceuticals, Inc.Horizant$38$14,27027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 210 neurology providers in Kentucky.

Other neurology in Somerset

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →